Santa Barbara Nutrients’ Scientists Awarded Breakthrough Patent Related to Polycystic Kidney Disease


University of California Professor, Dr. Thomas Weimbs, a recognized leader in the Polycystic Kidney Disease (PKD) research field and Dr. Jacob Torres, Head Researcher of Santa Barbara Nutrients (SBN), identified distinct metabolic polycystic kidney disease mechanisms that can be addressed by the unique formulation of two food ingredients that are Generally Recognized as Safe (GRAS): beta-hydroxybutyrate (BHB) and citrate. SBN’s first product, KetoCitra™, is a medical food for the dietary management of PKD and will be launched this year. KetoCitra™ is intended to be used under medical supervision and is covered by this new patent.

What is polycystic kidney disease (PKD)?

PKD is one of the most common, life-threatening genetic diseases, causing kidney enlargement and function loss over time. The disease affects over 600,000 Americans and 13 million people worldwide and is one of the leading causes of kidney failure requiring dialysis or kidney transplantation. There is no cure.

About KetoCitra™
The research by Dr. Weimbs and Dr. Torres showed that two natural compounds, beta-hydroxybutyrate (BHB) and citric acid (citrate), can help the nutritional management of PKD by addressing the metabolic abnormalities that manifest during the progression of the disease. KetoCitra is specifically designed with these two ingredients in a formulation that also delivers beneficial minerals and an alkaline load intended to support the balancing of urine pH.  The inclusion of calcium and magnesium helps to manage the dietary absorption of the renal stressors oxalate and inorganic phosphate.KetoCitra uses only ingredients that are generally recognized as safe (GRAS), is sodium- and sugar-free and formulated to be kidney-safe when used as directed. As a medical food, KetoCitra is to be taken under medical supervision. KetoCitra can be taken by itself but is recommended to be taken in conjunction with specific dietary and lifestyle changes. Researchers at SBN have collaborated with experienced renal dietitians to create a dietary program called Ren.Nu that is administered by the non-profit RenAlign. Patients in the Ren.Nu program, which launches in January 2022, learn to implement a plant-focused, kidney-safe ketogenic diet, together with KetoCitra, in a sustainable way.
“We are pleased that the U.S. Patent Office has recognized our unique research in understanding a complex disease like PKD. This is an important step in our company’s effort to bring affordable products to market that can bring hope to millions of people with PKD around the world,” said Dr. Weimbs, President and Founder of Santa Barbara Nutrients.
To read the full press release, follow this link: https://www.prweb.com/…/santa_barbara…/prweb18206928.htm

Leave a Reply

Your email address will not be published.

You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>